Multiple Sclerosis

^{[1] [2] [6] [16] [24] [8] [10]}

Meet the patient

A 28-year-old woman wakes with an ache behind the right eye that worsens on eye movement; over two days the vision blurs and the colours wash out so that a red pin looks grey. At the bedside the right pupil dilates when you swing the torch to it — a relative afferent pupillary defect. Six months ago she had a week of numbness in the left hand that "came right on its own".^[1]

This patient is built to test one question: is this optic neuritis in a young adult, disseminated in time and space — i.e. multiple sclerosis — and what do I do in the next two weeks, not the next two years? Hold that question and every section below slots into place.^[1]

Charcot's two principles — disseminated in time and space

MS is what happens when autoreactive lymphocytes attack oligodendrocyte myelin in the brain, optic nerves and spinal cord, leaving plaques in more than one place and more than one moment. The peripheral nervous system is spared — Schwann-cell myelin is not the target — which is why MS never causes a primary peripheral neuropathy.^[1][3]

Jean-Martin Charcot drew the two unifying principles from the autopsy table, and every diagnostic criterion since has been a refinement of them:^[1]

• Dissemination in space (DIS) — plaques in at least two of four typical CNS regions: periventricular, juxtacortical or cortical, infratentorial, and spinal cord.
• Dissemination in time (DIT) — plaques of different ages: a gadolinium-enhancing lesion beside a non-enhancing one, a new lesion on follow-up MRI, or CSF oligoclonal bands standing in for time.^[2]

The four skills that decide an MS case — none of which is "naming the disease": recognise the typical syndromes of a young adult; apply McDonald 2017 to lock the diagnosis at the first attack; exclude the mimics (above all NMOSD and MOGAD, because the wrong drug worsens the former); and choose and monitor a DMT with its specific risks — PML with natalizumab, autoimmunity with alemtuzumab, teratogenicity with teriflunomide.^[2][4]

Everyone forgets: MS is the commonest non-traumatic cause of neurological disability in young adults — about 2.8 million people worldwide — so the price of a wrong diagnosis is paid in decades, not years.^[1]

The four courses — read the backbone, not the label

About 85% begin relapsing-remitting; 10 to 15% are progressive from day one. The 2013 Lublin descriptors lay two extra axes — activity (relapse or new MRI lesion) and progression (worsening independent of relapse) — over the old relapsing-versus-progressive backbone, so a patient is now SPMS, active, progressing, not just SPMS.^[1]

Enlarge

The two Lublin axes in one line each:^[1]

• Activity — active means a relapse, a gadolinium-enhancing lesion, or a new or enlarging T2 lesion on MRI over a defined period; not active means none.
• Progression (progressive phenotypes only) — progressing means objectively worsening disability independent of relapse over a defined period; not progressing means stable.^[1]

When does RRMS convert to SPMS? Insidiously, and usually in retrospect: a sustained rise in EDSS over at least 6 to 12 months independent of relapses, with fewer gadolinium-enhancing lesions, more cognitive and progressive-motor burden, and reducing relapse frequency. Median time from onset was 10 to 20 years before DMTs and is lengthening with early high-efficacy therapy.^[4]

Who gets MS, and why it matters before you prescribe

MS picks young women three to one, loves the high latitudes, and is near-dependent on Epstein-Barr virus. Typical onset is 20 to 40 years (mean around 30); female-to-male ratio in RRMS is about 3:1, while PPMS runs closer to 1:1 and starts later, around 40.^[1][3]

The latitude gradient is the single most teachable epidemiology fact: prevalence climbs with distance from the equator — under 5 per 100,000 near it, over 200 per 100,000 in northern Europe, Canada and the northern US. Migration studies seal the case: move from a high- to a low-risk region before puberty and you take on the lower risk of your new home; move after age 15 and you carry your birthplace's risk — pointing straight at an adolescent environmental exposure, chiefly Epstein-Barr virus and vitamin D / UV sunlight.^[3][4]

^[1]

Genetic and environmental risk factors — group them as 'genes, a virus, and three modifiable exposures':^[1]

• Genetic — strongest association is HLA-DRB1*15:01 (the major susceptibility allele); over 200 other non-HLA loci, mostly immune genes, add small effects. Family history raises risk from a population baseline of about 0.1% to about 2 to 4% with one affected first-degree relative, and to about 25 to 30% in a monozygotic twin.
• Epstein-Barr virus (EBV) — infection is almost universal in MS; infectious mononucleosis multiplies the risk several-fold over asymptomatic primary EBV. EBV is now regarded as a near-necessary trigger.
• Vitamin D and sunlight — low UV exposure and low 25-hydroxy-vitamin D levels (and the latitude gradient) are independent risk factors.
• Smoking — raises the risk of developing MS, accelerates conversion from CIS to MS, and accelerates progression to SPMS.
• Adolescent obesity — independent risk factor, especially in girls.
• Female sex — strong risk factor for relapsing disease.^[1]

What twin concordance tells you: monozygotic concordance (about 25 to 30%) dwarfs dizygotic (about 3 to 5%), so genes matter — but it is far below 100%, so MS is not Mendelian. A genetically susceptible host still needs the environmental trigger (EBV, low vitamin D, smoking) to manifest.^[1]

The plaque in six steps — and why the axon is what is lost

An MS plaque is perivenular inflammatory demyelination that, acutely, spares the axon and, chronically, loses it. Self-tolerance to myelin antigens (myelin basic protein, proteolipid protein, myelin oligodendrocyte glycoprotein) breaks down, an autoreactive T-cell response forms, and the CNS is attacked.^[1][3]

The immunopathological sequence of an acute plaque — six steps, viva-perfect:^[1]

1. Loss of self-tolerance in a genetically susceptible host (HLA-DRB1*15:01) after an environmental trigger (EBV, low vitamin D).
2. Autoreactive CD4+ T-helper cells — chiefly Th1 (IFN-gamma) and Th17 (IL-17) — activate in the periphery and cross the blood-brain barrier; its disruption with gadolinium leakage is the radiological hallmark of an active lesion.
3. Inside the CNS, T-cells are re-stimulated by antigen-presenting cells (microglia, macrophages, dendritic cells) presenting myelin peptides on HLA class II.
4. Macrophage- and antibody-mediated myelin destruction: CD8+ cytotoxic T-cells, macrophages and antibodies (with complement) strip myelin from axons; oligodendrocytes are lost, and CD4+ T-cells recruit B-cells and plasma cells that make oligoclonal IgG within the CNS.
5. Acute plaque histology — perivenular inflammatory infiltrate with demyelination but relative preservation of axons (the lesion is demyelinating, not primarily axonal), plus oedema and gadolinium enhancement.
6. Chronic plaque histology — inflammation resolves; gliosis, astrogliosis and permanent axonal loss dominate, leaving a sharply demarcated grey-pink glial scar (the sclerosis). Shadow plaques (thinly remyelinated axons) mark partial remyelination.^[1]

Enlarge

Two overlapping disease processes run across the whole course:^[1][4]

• Focal inflammatory relapses — autoreactive T- and B-cells, blood-brain-barrier breakdown, gadolinium-enhancing lesions. This dominates early RRMS and is what relapse steroids and most DMTs target.
• Diffuse smouldering neurodegeneration — meningeal lymphoid aggregates, microglial activation, mitochondrial injury, chronic axonal loss and brain atrophy. This dominates progressive MS (PPMS, SPMS) and is the substrate of the irreversible disability that current DMTs only partly touch.^[1]

How demyelination produces symptoms — four mechanisms, all examinable:^[1]

• Conduction block — demyelinated axons lose saltatory conduction and impulses fail to propagate; this is the mechanism of an acute relapse deficit (weakness in transverse myelitis, visual loss in optic neuritis).
• Ectopic discharges — demyelinated axons fire spontaneously, producing positive symptoms: Lhermitte's sign and paroxysmal phenomena (trigeminal neuralgia, tonic spasms).
• Heat sensitivity (Uhthoff's phenomenon) — small rises in body temperature further impair conduction in marginally demyelinated axons, transiently worsening pre-existing deficits.
• Axonal loss — irreversible; explains deficits that never recover and progressive disability. The axon is the unit of permanent disability, which is why protecting axons with early, high-efficacy DMT is the modern therapeutic goal.^[1]

Meet the syndromes — optic nerve, cord, brainstem

MS presents in a young woman (20 to 40) with episodic deficit that comes on over hours to days, lasts over 24 hours, and recovers over weeks — and the syndrome tracks the plaque's location. Know three first-presentation syndromes cold.^[1][4]

1. Optic neuritis — the single most common first event.^[1]

• Painful, unilateral, subacute visual loss — periocular pain exacerbated by eye movement.
• Reduced colour vision (dyschromatopsia) — red desaturation (reds look washed out) is a sensitive early sign; test each eye with a red pin.
• Relative afferent pupillary defect (RAPD) — the swinging-flashlight test shows the affected pupil dilating when light reaches it (afferent limb defect; optic nerve lesion).
• Visual field defect — typically a central scotoma; diffuse depression also common.
• Fundus — papillitis (swollen disc) if anterior (intraocular), retrobulbar (normal disc, "patient sees nothing, doctor sees nothing") if posterior; optic atrophy (pale disc) develops later.
• Recovery begins within weeks and over 90% recover useful vision; severe bilateral optic neuritis with poor recovery should send you hunting for NMOSD or MOGAD.^[1]

2. Partial transverse myelitis — a focal spinal-cord plaque.^[1]

• Paraparesis or monoparesis with upper motor neuron signs (spasticity, hyperreflexia, extensor plantar/Babinski); an acute lesion may transiently cause flaccidity and areflexia ("spinal shock").
• Sensory level — a band of altered sensation at the lesion with loss below.
• Sphincter disturbance — bladder urgency, hesitancy, retention; constipation.
• Lhermitte's sign if the plaque is in the cervical cord.^[1]

3. Brainstem and cerebellar syndromes — where INO lives.^[1]

• Internuclear ophthalmoplegia (INO) — weakness of adduction on horizontal gaze (medial longitudinal fasciculus lesion) with nystagmus in the abducting eye and preserved convergence; bilateral INO in a young adult is highly suggestive of MS.
• Diplopia, vertigo, facial sensory loss, lower-motor-neuron facial palsy.
• Cerebellar signs — ataxia, intention tremor, dysmetria (finger-nose), dysdiadochokinesia, scanning dysarthria (explosive, broken-up speech).^[1]

Two eponymous phenomena — be precise, examiners always ask:^[1]

• Lhermitte's sign — an electric-shock-like sensation radiating down the spine and sometimes into the limbs on neck flexion, from mechanical irritation of demyelinated axons in a cervical cord plaque. It is a sign you demonstrate, not a symptom you ask about — flex the neck and watch the face.
• Uhthoff's phenomenon — a transient worsening of existing symptoms (especially vision) on raising body temperature (exercise, hot bath, fever), from heat-induced conduction block in demyelinated axons; it resolves on cooling. Lhermitte you demonstrate, Uhthoff you infer from heat.^[1]

^[1]

Non-focal or 'invisible' symptoms — often the most disabling, and the easiest to miss:^[1]

• Fatigue — the commonest and most disabling symptom for many; distinct from depression or sleepiness.
• Spasticity — velocity-dependent increased tone, painful flexor spasms.
• Bladder dysfunction — overactive (urgency, frequency, incontinence) from detrusor overactivity, or underactive (retention, overflow), plus detrusor-sphincter dyssynergia.
• Bowel — constipation (common).
• Sexual dysfunction — erectile dysfunction in men; loss of libido and arousal in women.
• Cognitive impairment — slowed processing speed, attention and memory deficits in 40 to 70%; can occur early.
• Depression — common, and suicide risk is elevated — screen every visit.
• Heat intolerance and exercise-related worsening.
• Neuropathic pain — trigeminal neuralgia (often bilateral in MS), Lhermitte, painful tonic spasms.^[1]

Atypical presentations — the examiner will probe these:^[1]

• Paediatric MS — first event often ADEM-like (encephalopathy, multifocal deficits); more inflammatory, higher relapse rate, better recovery per attack, but a longer lifetime to accrue disability. Refer to a paediatric MS specialist.
• Late-onset MS or PPMS — onset over 40 with progressive (not relapsing) myelopathy, often mislabelled cervical spondylosis or vascular disease; more often male and PPMS.
• Tumefactive MS — a single large (over 2 cm) mass-like plaque with oedema and ring enhancement mimicking tumour or abscess; MR spectroscopy, perfusion and evolution usually spare the biopsy.
• Trigeminal neuralgia in a young adult (under 40), or bilateral trigeminal neuralgia — strongly suggests MS.
• Pregnancy-related relapse pattern — rate falls in the third trimester and rebounds in the first 3 months postpartum (see Special populations).^[1]

The killer mimics — MS vs NMOSD vs MOGAD

The differential that can ruin a career is MS vs NMOSD vs MOGAD, because the treatments diverge and interferon-beta worsens NMOSD. A young adult with recurrent CNS demyelination has a wide list, but this face-off is the one you must settle before any DMT.^[2][4]

The one-line discriminator: AQP4-IgG positive plus a longitudinally extensive transverse myelitis (over 3 segments, central cord) is NMOSD — not MS — and interferon-beta will worsen it.^[2][4]

Mimics to exclude by blood test BEFORE starting any DMT: vitamin B12, ANA and extractable nuclear antigens, ACE (sarcoid), AQP4-IgG (NMOSD), MOG-IgG (MOGAD), HIV, syphilis (Treponema pallidum serology), Lyme serology where endemic, and TSH.^[2]

The bedside round — and the EDSS 6 milestone

Bedside examination in MS confirms the lesion, maps disability, and above all hunts the red flags that point away from MS toward NMOSD or MOGAD. Run vision, eye movements, cranial nerves, motor, cerebellar, sensory, gait and Lhermitte's manoeuvre:^[4]

• Visual acuity (Snellen, with and without pinhole), colour vision (Ishihara; red desaturation with a red pin in each eye), visual fields (confrontation).
• RAPD by the swinging-flashlight test — the affected pupil dilates when light reaches it; the single most useful bedside sign of optic neuritis.
• Eye movements for internuclear ophthalmoplegia (impaired adduction, abducting nystagmus, preserved convergence) and other ocular motor palsies.
• Cranial nerves — facial sensation (test trigeminal trigger zones), facial power, hearing, palatal and tongue movement.
• Motor — tone (spasticity), power, reflexes (hyperreflexia), plantar response (extensor/Babinski in a UMN lesion), abdominal reflexes (often lost below a cord lesion).
• Cerebellar — finger-nose (dysmetria, intention tremor), heel-shin, rapid alternating movements (dysdiadochokinesia), wide-based ataxic gait, scanning dysarthria.
• Sensory — pinprick and temperature (spinothalamic), joint position and vibration (posterior columns); map a sensory level if myelopathy.
• Gait, including tandem walking.
• Lhermitte's manoeuvre — ask the patient to flex the neck; an electric shock down the spine is a positive Lhermitte's sign (cervical cord plaque).
• Bladder scan (post-void residual) if urinary symptoms.^[1]

Expanded Disability Status Scale (EDSS, Kurtzke) — the number in every clinic letter and trial:^[1]

• 0 = normal neurological examination.
• 1.0 to 3.5 = mild disability, fully ambulatory (most RRMS patients sit here).
• 4.0 = fully ambulatory without aid, up and about over 12 hours a day despite relatively severe disability.
• 5.0 = ambulatory without aid for about 200 m; disability severe enough to impair full daily activities.
• 6.0 = needs a unilateral aid (cane, crutch or single walker) to walk about 100 m — the landmark milestone, and often the trigger for DMT escalation and rehabilitation.
• 6.5 = bilateral aid to walk about 20 m.
• 7.0 = unable to walk beyond 5 m even with aid; essentially wheelchair-bound; wheels self and transfers alone.
• 8.0 = essentially restricted to bed or chair; may be out of bed much of the day; retains many self-care functions; generally effective use of arms.
• 8.5 = restricted to bed much of the day; some effective use of arm(s).
• 9.0 = helpless bed patient; can communicate and eat.
• 9.5 = totally helpless bed patient; unable to communicate or eat or swallow.
• 10.0 = death due to MS.^[1]

The EDSS number to carry into the viva is 6 — unilateral aid to walk 100 m — because it is the milestone that reshapes a life and the threshold that reshapes your DMT plan.^[1]

Bedside red flags pointing AWAY from MS toward NMOSD or MOGAD: severe or bilateral optic neuritis with poor recovery; longitudinally extensive transverse myelitis (cord lesion over 3 vertebral segments); area postrema syndrome (intractable hiccups or nausea); rapid, severe disability accrual; AQP4-IgG or MOG-IgG positivity.^[1]

Investigations — MRI, CSF, and McDonald 2017 verbatim

MS is diagnosed clinically with MRI support — there is no single confirmatory test, and McDonald 2017 is the anchor you reproduce verbatim.^[1][2]

First-line investigations for suspected MS:^[1]

• MRI brain and whole spinal cord with gadolinium — the cornerstone.
• CSF analysis (lumbar puncture) — when MRI is inconclusive or NMOSD/MOGAD is in question.
• Visual evoked potentials (VEP) — a delayed P100 latency confirms optic-nerve demyelination even after recovery (useful for historic DIS).
• Bloods to exclude mimics — FBC, ESR, CRP, vitamin B12, ANA, ACE, TSH, AQP4-IgG, MOG-IgG, HIV, syphilis, Lyme where endemic.^[1]

Typical MRI lesion locations and signs — Dawson fingers is the phrase that scores marks:^[1]

• Periventricular ovoid lesions perpendicular to the ventricle — Dawson fingers (perivenular inflammation along deep medullary veins).
• Juxtacortical or cortical lesions (cortical lesions were added to the 2017 McDonald DIS criteria).
• Infratentorial — cerebellar peduncles, pons, brainstem.
• Spinal cord — typically cervical, short (under 2 vertebral segments), peripheral, asymmetric (contrast the longitudinally extensive central cord lesion of NMOSD).
• Gadolinium enhancement marks an active lesion with blood-brain-barrier breakdown — i.e. dissemination in time when it sits beside non-enhancing lesions.
• T1 black holes = permanent axonal loss; brain atrophy = neurodegeneration.^[1]

CSF findings in MS — always send a matched serum sample:^[1]

• Oligoclonal bands present in CSF but NOT in matched serum = intrathecal IgG synthesis — the hallmark, positive in over 95% of established MS.
• Raised IgG index (over 0.7) — corroborates intrathecal synthesis.
• Mild lymphocytosis (under 50 cells per microlitre), normal glucose, normal or mildly raised protein.
• Bands in both CSF and serum mean a systemic, not intrathecal, response and argue against MS.^[1]

The McDonald 2017 diagnostic criteria — reproduce verbatim, this is the high-yield answer:^[2]

Dissemination in space (DIS) — at least one T2-hyperintense lesion in at least two of four areas: (1) periventricular, (2) juxtacortical or cortical, (3) infratentorial, (4) spinal cord. (CSF oligoclonal bands can substitute for DIS in PPMS.)^[1]

Dissemination in time (DIT) — demonstrated by any of:^[2]

1. Simultaneous gadolinium-enhancing and non-enhancing lesions at any time, OR
2. A new T2-hyperintense or gadolinium-enhancing lesion on follow-up MRI versus the baseline scan, irrespective of timing, OR
3. CSF-specific oligoclonal bands (which can substitute for DIT — a key 2017 change).^[2]

The four changes that make McDonald 2017 different from 2010 — examiners test these:^[2]

• CSF oligoclonal bands can substitute for dissemination in time in all phenotypes (not just PPMS).
• Symptomatic lesions — those matching the presenting syndrome — now count toward DIS and DIT (they were excluded in 2010).
• Cortical lesions were added alongside juxtacortical in the DIS criteria.
• Diagnosis of MS is now possible at the first attack (CIS) if criteria are met — enabling earlier DMT.^[1]

Diagnostic criteria for PPMS: at least one year of disease progression (retrospectively or prospectively determined) plus at least two of — (a) at least one T2-hyperintense brain lesion in a typical MS region; (b) at least two T2-hyperintense spinal-cord lesions; (c) CSF-specific oligoclonal bands.^[2]

When are AQP4 and MOG antibodies checked? In every patient with suspected MS who carries an atypical feature — severe or bilateral optic neuritis, longitudinally extensive transverse myelitis, area postrema syndrome, poor recovery, or a monophasic ADEM-like picture — and ideally in all newly diagnosed patients before any DMT, because misdiagnosing NMOSD as MS and giving interferon worsens the disease.^[1]

The acute relapse — steroids buy time, not outcome

An acute MS relapse is high-dose IV methylprednisolone to speed recovery; it buys function, it does not buy a better final outcome. Most patients are not acutely unwell at diagnosis, but a severe relapse — transverse myelitis with paralysis, brainstem relapse with respiratory compromise, vision-threatening optic neuritis — is a medical emergency with a structured response.^[3][4]

Enlarge

^{[10] [13] [16] [17] [19]}

The first moves in a severe relapse:^[3][4]

• ABCDE — secure airway and breathing (a high cervical cord lesion can compromise respiration); assess circulation and disability.
• Screen for and treat infection — the commonest relapse trigger is a urinary tract or respiratory infection; send urine and blood cultures, FBC, CRP, and treat promptly.
• Urgent MRI brain and spine with gadolinium — confirm the acute demyelinating lesion and exclude a mimic (compressive myelopathy, infarct, abscess).
• Urgent neurology referral and admission for severe relapse (paralysis, vision-threatening optic neuritis, sphincter involvement).^[1]

Acute relapse regimen — high-dose IV methylprednisolone:^[8][10]

• Drug: methylprednisolone — 1000 mg (1 g) intravenously once daily (the ONTT regimen; the apheresis meta-analysis likewise defines first-step relapse therapy as high-dose IV methylprednisolone up to 1000 mg daily over three to five days).^[8][11]
• Route: intravenous infusion over at least 30 to 60 minutes. High-dose oral methylprednisolone is a reasonable alternative in milder relapses — a Cochrane review of five randomised trials found no significant difference in relapse recovery, MRI activity or adverse events between oral and intravenous routes.^[9]
• Duration: the classic ONTT course is 3 consecutive days, followed by an oral prednisone taper; contemporary practice commonly extends the IV course to 3 to 5 days for severe attacks.^[8]
• Rationale: speeds recovery — in the ONTT, visual function recovered faster with IV methylprednisolone than placebo (particularly reversal of visual-field defects), with slightly better visual fields, contrast sensitivity and colour vision at six months.^[8]
• Limits: does NOT change long-term outcome or final disability — it buys time and function, not disease modification; oral prednisone alone was ineffective and increased new episodes of optic neuritis in the ONTT. Say this honestly to patients.^[8][10]
• Cover with it: PPI (gastroprotection), mood and glucose monitoring, blood-pressure monitoring, and bone health with repeated courses (osteoporosis risk).^[10]

Steroid-refractory severe relapse — add plasma exchange (PLEX):^[11]

• Regimen: 5 to 7 exchanges over 10 to 14 days (typically every other day) — the regimen used in the landmark randomised trials of apheresis in steroid-refractory CNS demyelinating attacks.^[12]
• Indications: severe, steroid-refractory relapse (especially optic neuritis and transverse myelitis), tumefactive demyelination, steroid-resistant NMOSD or MOGAD attack.
• Rationale: removes circulating antibodies, complement and cytokines — it addresses the humoral component. In a meta-analysis of over 1,300 patients with acute glucocorticosteroid-unresponsive MS relapses or CIS, roughly three-quarters of patients responded to plasma exchange; in the randomised trial of immunoadsorption versus plasma exchange, both produced significant functional improvement at four weeks.^[11][12]

Corticosteroid safety, every course: gastroprotection (PPI), blood-glucose monitoring (steroid hyperglycaemia), blood-pressure monitoring, mood monitoring (steroid-induced psychosis or depression — especially relevant in MS, where depression is common), bone protection with repeated courses (calcium and vitamin D, bisphosphonate if needed), and screening for latent infection (TB, hepatitis).^[1]

The DMT ladder — from safe injectables to monoclonal antibodies

MS management has three pillars: treat the acute relapse, suppress the disease with a DMT, and manage symptoms and rehabilitation in parallel. The DMT ladder runs from injectable platform drugs through oral agents to monoclonal antibodies — with a modern push toward early high-efficacy induction in active disease.^[1][5][6]

The DMT classes and escalation ladder — know each drug, its dose, route, and the monitoring it forces on you:^[1]

A. Injectable platform drugs — mild-to-moderate efficacy, excellent safety, first-line in many:^[1]

• Interferon-beta — IFN-beta-1a 30 mcg intramuscularly once weekly, IFN-beta-1a 44 mcg subcutaneously three times weekly, or IFN-beta-1b 250 mcg subcutaneously every other day. The pivotal trials each cut relapse rates by roughly one-third versus placebo (IFNB: annual exacerbation rate 0.84 vs 1.27; PRISMS: relapses down 33% at the 44 mcg dose). Side effects: flu-like illness after each injection, injection-site reactions, depression, transaminitis, and neutralising antibodies that blunt efficacy.^[13][14]
• Glatiramer acetate — 20 mg subcutaneously daily (the dose tested in PreCISe and the CONFIRM reference arm). Similar efficacy to interferon; injection-site reactions and a benign immediate post-injection systemic reaction (chest tightness, flushing). Considered the safest in pregnancy if a DMT is needed.^[15][17]

B. Oral agents — moderate-to-high efficacy:^[1]

• Fingolimod 0.5 mg orally once daily — a sphingosine-1-phosphate receptor modulator that prevents lymphocyte egress from lymph nodes. In FREEDOMS, the annualised relapse rate fell to 0.18 versus 0.40 with placebo, with reduced disability progression. First-dose cardiac monitoring for at least 6 hours (bradycardia and atrioventricular conduction block occurred at initiation in the trial); risk of macular oedema (baseline and 3-to-4-month eye exam), raised liver-enzyme levels, mild hypertension, and a small PML risk. Teratogenic — contraception required.^[16]
• Dimethyl fumarate 240 mg orally twice daily — activates the Nrf2 antioxidant pathway. In DEFINE, the annualised relapse rate was 0.17 versus 0.36 on placebo (a 53% relative reduction). Side effects: flushing and GI events (the dominant adverse events in DEFINE and CONFIRM), decreased lymphocyte counts (monitor the count; PML risk if profound), and elevated aminotransferases.^[17][28]
• Teriflunomide 7 mg or 14 mg orally once daily — inhibits pyrimidine synthesis in proliferating lymphocytes. In TEMSO both doses cut the annualised relapse rate by about one-third versus placebo (0.37 vs 0.54); diarrhoea, nausea, hair thinning and elevated ALT were more common than placebo. Strongly teratogenic (long washout or cholestyramine before conception); monitor LFTs; causes alopecia, hypertension, peripheral neuropathy.^[18]

C. Monoclonal antibodies — high efficacy, for escalation or induction:^[1]

• Natalizumab 300 mg IV every 4 weeks — anti-alpha-4 integrin blocks T-cell crossing of the blood-brain barrier. In AFFIRM, natalizumab cut the one-year relapse rate by 68% and reduced two-year sustained disability progression by 42%. PML risk is stratified by anti-JC virus antibody status and treatment duration — JCV-negative patients carry very low risk (97% of baseline JCV-negative patients stayed negative or below the risk-index threshold over 18 months in AFFIRM/STRATIFY-1); JCV-positive patients over 24 months on treatment, especially with prior immunosuppression, carry risk up to about 1 in 100, and index-stratified monitoring further reduces incidence.^[19][7][21]
• Ocrelizumab 600 mg IV every 24 weeks (the first 600 mg dose divided into two 300 mg infusions two weeks apart, then single 600 mg infusions) — anti-CD20 B-cell depletion. Approved for relapsing MS (OPERA I and II) AND for PPMS (ORATORIO) — the only approved DMT for PPMS. In OPERA both trials cut the annualised relapse rate roughly in half versus interferon-beta-1a (46 to 47% lower), with less 12-week confirmed disability progression (hazard ratio 0.60); ORATORIO lowered the risk of 12-week confirmed disability progression by 24% versus placebo in PPMS (32.9% vs 39.3%; hazard ratio 0.76). Watch for infusion reactions, hepatitis B reactivation (screen HBV first — active hepatitis B contraindicates therapy), modest infection risk, and low PML risk.^[5][6]
• Alemtuzumab 12 mg per day IV for 5 days (course 1), then 3 days at 12 months (course 2) — anti-CD52 lymphocyte depletion; very high efficacy, used as induction in highly active disease. In CARE-MS I the relapse rate was 55% lower than weekly interferon-beta-1a over two years; major risk is secondary autoimmunity (immune thrombocytopenia in about 1%, thyroid disease in up to about one in five by two years) — it demands monthly blood and urine monitoring for 4 years after the last course. Largely second-line now on its safety profile.^[20][32]
• Mitoxantrone — a chemotherapeutic, now rarely used (cardiotoxicity, treatment-related acute leukaemia); largely superseded.^[1]

Escalation versus early high-efficacy induction — the live debate: the classic model steps from platform drugs to oral agents to monoclonal antibodies at the first sign of breakthrough disease (clinical relapse or new MRI activity). The modern induction paradigm starts a high-efficacy DMT (natalizumab, ocrelizumab, alemtuzumab) early in highly active MS, on the rationale that preventing early axonal loss preserves long-term function. AHSCT (autologous haematopoietic stem cell transplant) is reserved for very active, treatment-refractory disease in specialist centres.^[5]

Symptomatic management — know the drug, dose and rationale. The evidence base for pharmacologic symptom control is thinner than for DMTs — trials are small and often open-label — but a structured approach is standard practice:^[1][26]

• Spasticity — baclofen (start 5 mg three times daily, titrate to 60 to 100 mg per day in divided doses; intrathecal baclofen pump for severe), tizanidine 2 to 4 mg up to 36 mg per day, stretching and physiotherapy; botulinum toxin for focal spasticity.^[26]
• Fatigue — amantadine 100 mg once or twice daily (modest benefit); treat anaemia, thyroid and sleep disorders; graded exercise.^[26]
• Overactive bladder — oxybutynin 5 mg two to three times daily (or tolterodine, solifenacin, mirabegron); clean intermittent self-catheterisation if retention or high post-void residual.^[26]
• Neuropathic pain — gabapentin (start 300 mg at night, titrate to 1800 to 3600 mg per day) or pregabalin, amitriptyline 10 to 75 mg at night, carbamazepine for trigeminal neuralgia.^[26]
• Erectile dysfunction — sildenafil 25 to 100 mg before intercourse.^[26]
• Depression — SSRIs (sertraline, citalopram); CBT; screen for suicidality.
• Constipation — bulk-forming laxatives, macrogols.^[1][26]

DMT monitoring — each drug owns a different panel. The most demanding schedule belongs to alemtuzumab: complete blood counts, serum creatinine with urinalysis, and thyroid-function tests before treatment and monthly until 48 months after the last infusion, because secondary autoimmunity (thyroid disease in roughly a third of patients, immune thrombocytopenia in about 1%, rare anti-GBM nephropathy) can appear years later.^[32]

• MRI surveillance — baseline, then typically at 6 months after starting a new DMT, then annually (more often if breakthrough activity is suspected); compare for new T2 lesions or gadolinium enhancement.
• JCV antibody status (natalizumab) — re-test every 6 months (seroconversion raises PML risk; the consensus algorithm adds anti-JCV antibody index testing and index-stratified MRI frequency, with 3-to-4-monthly scans for index over 1.5 beyond 18 months of treatment).^[21]
• Lymphocyte counts (dimethyl fumarate, fingolimod) — every 3 to 6 months; suspend if profound lymphopenia.
• Liver function — baseline and periodically (interferon, teriflunomide, dimethyl fumarate).^[16][17][18]
• Eye exam — baseline and at 3 to 4 months (fingolimod, for macular oedema).^[16]
• HBV and TB screen before ocrelizumab or rituximab (reactivation risk; active hepatitis B contraindicates anti-CD20 therapy until resolved).^[30]

Rebound risk — the classic trap: never stop natalizumab or fingolimod abruptly. Stopping either can trigger a severe rebound of disease activity — reactivation exceeding the pre-treatment baseline, typically within 2 to 4 months of stopping fingolimod (severe-relapse rates of roughly 10 to 25% in discontinuation cohorts) — and rebound after natalizumab withdrawal is widely reported; if treatment must stop — especially in a JCV-positive patient coming off natalizumab — plan a bridge to another high-efficacy DMT such as ocrelizumab.^[27][21]

Specific subtypes and scenarios

The phenotype decides the DMT — PPMS has exactly one option, ocrelizumab.^[1]

Complications — and the preventable-harm list

Most MS morbidity is accrued disability and its complications; the preventable part is almost always a diagnostic or prescribing error.^[1]

Complications of the disease itself:^[1]

• Progressive neurological disability — accumulating motor, sensory, visual, cerebellar and cognitive impairment; wheelchair dependence; loss of independence.
• Osteoporosis — from immobility and repeated corticosteroid courses; fracture risk.
• Infection — urinary tract (retention, catheters), chest (aspiration, weak cough), pressure-area (immobility); infection is the leading cause of MS-related hospitalisation and a frequent relapse trigger.
• Depression and raised suicide risk — screen every visit; SSRIs and CBT.
• Pressure sores, contractures and deep vein thrombosis — from immobility and spasticity.
• Aspiration pneumonia — from brainstem or bulbar disease.^[1]

Progressive multifocal leukoencephalopathy (PML) — the feared complication of natalizumab, and rarely of dimethyl fumarate, rituximab and ocrelizumab. This section carries no humour; it is a genuine threat to the patient and to the prescribing decision.^[7]

• Cause — reactivation of JC virus (John Cunningham virus), a polyomavirus that infects oligodendrocytes and causes progressive demyelination in the immunosuppressed.
• Clinical features — subacute progressive neurological deterioration over weeks: new cognitive decline, hemiparesis, visual field deficits, aphasia, ataxia, seizures — distinct from a typical MS relapse.
• Diagnosis — MRI shows large, confluent, asymmetric T2-hyperintense subcortical white-matter lesions (often frontal or parieto-occipital), typically without mass effect and without enhancement (rim enhancement appears as immunity recovers); CSF JCV DNA by PCR is sensitive and specific. The anti-JCV antibody index stratifies risk before natalizumab starts.
• Risk stratification (natalizumab) — JCV-antibody-negative patients carry very low risk (under 1 in 10,000); JCV-positive patients carry higher risk that rises with treatment duration (over 24 months) and prior immunosuppression (the highest-risk stratum, over 1 in 100).^[7]
• Management — stop the offending drug, plasma exchange to accelerate clearance (watch for immune reconstitution inflammatory syndrome, IRIS), and supportive care. Mortality is high.^[7]

The preventable-harm list — every line is examinable, every line is avoidable:^[1]

• Misdiagnosing NMOSD or MOGAD as MS and giving interferon-beta, which worsens the disease — exclude AQP4 and MOG antibodies first.^[4]
• Missing an infection-triggered relapse — treating a UTI-driven relapse with steroids alone without treating the UTI.
• Stopping natalizumab or fingolimod abruptly — severe rebound of disease activity; always plan a bridge.
• Over-diagnosing MS on incidental MRI white-matter change (age-related small-vessel disease, migraine) — apply McDonald strictly; Dawson-finger morphology, cortical or juxtacortical lesions, and CSF oligoclonal bands discriminate.
• Confusing a pseudo-relapse with a true relapse — fever, infection or heat (Uhthoff) can transiently re-emerge old symptoms; a true relapse is new or worsening deficit over 24 hours without fever or infection.
• Forgetting vitamin D supplementation and smoking cessation as modifiable prognostic measures.^[1]

Prognosis and disposition

Prognosis in MS is read off the onset phenotype, the early relapse pattern, and the recovery from the first attack. Favourable: female sex, young onset (under 30), relapsing-remitting course, low early relapse rate, optic neuritis or sensory onset (better than motor or cerebellar), complete recovery from the first attack, longer first inter-attack interval, high CSF oligoclonal bands without atrophy, non-smoker, adequate vitamin D.^[1][4]

Adverse: male sex, older onset (over 40), primary progressive course, frequent early relapses, motor, cerebellar or sphincter onset, incomplete recovery, early brain atrophy and spinal-cord lesions, smoking, low vitamin D.^[1]

Disability milestones (pre-DMT, historical): median time from onset to EDSS 6 (cane) was about 15 years, and to EDSS 8 (bed or wheelchair) about 30 years; median survival was reduced by about 7 to 10 years versus the general population, chiefly from complications (infection, aspiration). In the modern DMT era these milestones are being pushed back — earlier high-efficacy therapy substantially cuts relapse rate and delays disability, though no randomised data yet span decades.^[5]

The pregnancy relapse pattern — know it cold: the rate falls by about 70% in the third trimester, then rebounds above pre-pregnancy rates in the first 3 months postpartum before returning to baseline by 6 to 12 months. Exclusive breastfeeding may modestly reduce postpartum relapses; IV methylprednisolone is safe postpartum and in breastfeeding (delay a feed for a few hours after the infusion).^[1]

Disposition and follow-up:^[1]

• Lifelong specialist neurology monitoring — annual review at minimum, with a named MS nurse for between-visit access.
• Admit for severe relapse (paralysis, vision-threatening optic neuritis, respiratory compromise), suspected PML, or systemic complication (sepsis, aspiration).
• Suicide-risk screening at every visit — depression and suicide are over-represented in MS.
• Multidisciplinary team — MS nurse, physiotherapy, occupational therapy, continence services, psychology, speech and language therapy, social work.
• Advance care planning for advanced disease (feeding, ventilation preferences).^[1]

Special populations — pregnancy above all

MS in pregnancy is a near-guaranteed exam question, and the answers are a small, memorisable set. The relapse-rate falls through pregnancy (lowest in the third trimester) and rebounds in the first three months postpartum — the PRIMS study quantified this at 0.2 relapses per year in the third trimester versus 0.7 before pregnancy, rising to 1.2 in the first three months postpartum.^[4][22]

• Pre-conception — stop teratogenic DMTs with an adequate washout before trying to conceive: teriflunomide (accelerated elimination with cholestyramine, or wait up to two years for the slow natural washout), fingolimod (washout before conception), mitoxantrone (long). Confirm disease stability before planned conception.^[23]
• Safest DMT in pregnancy — interferon-beta and glatiramer acetate have the most reassuring registry and cohort data; recent French registry data suggest continuing interferon-beta or glatiramer acetate into pregnancy, or natalizumab until the third trimester, lowers relapse risk versus stopping treatment.^[23][27]
• Relapse pattern — in PRIMS the relapse rate fell during pregnancy (lowest in the third trimester) and rose to about 1.2 relapses per woman-year in the first three months postpartum before returning to baseline; a 2020 meta-analysis confirmed the same pattern across more than 7,000 pregnancies.^[22][24]
• Relapse treatment in pregnancy — IV methylprednisolone; monthly IV corticosteroids after delivery reduced postpartum relapses in one small controlled study. Avoid steroids in the first trimester where possible.^[10][25]
• Anaesthesia — epidural or spinal anaesthesia is safe; neither epidural analgesia nor breastfeeding increased relapse risk or disability progression in PRIMS.^[22]
• Breastfeeding — generally encouraged and safe with glatiramer; restart DMT promptly postpartum if disease is active, given the rebound risk.^[1][23]

Paediatric MS: more inflammatory, an ADEM-like first event with encephalopathy, higher relapse rate, better recovery per attack but a longer lifetime of disease to manage. Refer to a paediatric MS specialist; fingolimod and teriflunomide are the two DMTs tested in large phase III trials and approved for paediatric use, with dimethyl fumarate and the high-efficacy agents used off-label or in later trials.^[29]

Late-onset MS (over 40) and male sex: more often primary progressive, more spinal-cord predominant, worse prognosis, and more easily misdiagnosed as cervical spondylotic myelopathy or vascular disease. The focus shifts to rehabilitation and symptom management alongside ocrelizumab for PPMS.^[1]

Family planning — the teratogenic DMT list: teriflunomide (contraindicated in pregnancy; accelerated elimination available), fingolimod, and mitoxantrone (alemtuzumab and ocrelizumab are withheld for lack of safety data or fetal B-cell depletion). Glatiramer and interferon-beta carry the most reassuring reproductive safety data.^[23][30]

Immunocompromised or co-morbid patients: screen for hepatitis B, hepatitis C and latent TB before anti-CD20 therapy (ocrelizumab, rituximab) or alemtuzumab — active hepatitis B contraindicates anti-CD20 therapy until resolved — avoid live vaccines during and after B-cell-depleting therapy; manage cardiovascular risk aggressively, because vascular comorbidity accelerates MS disability.^[30][32]

Evidence, guidelines, and regional differences

McDonald 2017 is the international diagnostic standard, and two NEJM trials — OPERA and ORATORIO — reshaped the DMT landscape.^[2]

The McDonald 2017 revisions (Thompson et al., Lancet Neurology 2018) are the diagnostic anchor. The four changes from 2010: CSF oligoclonal bands can substitute for DIT in all phenotypes; symptomatic lesions count toward DIS and DIT; cortical lesions were added to juxtacortical in DIS — together allowing earlier, MRI-supported diagnosis at CIS.^[2]

Landmark DMT trials — know the design and the headline result:^[1]

• ORATORIO (Montalban et al., NEJM 2017) — ocrelizumab vs placebo in PPMS: reduced the risk of confirmed disability progression at 12 weeks by 24% (and at 24 weeks by 25%); the first DMT to work in PPMS, and the basis of its licensing as the only approved PPMS DMT.^[6]
• OPERA I and II (Hauser et al., NEJM 2017) — ocrelizumab vs interferon-beta-1a in RRMS: cut the annualised relapse rate by about 46 to 47% and reduced disability progression and MRI activity versus interferon — establishing ocrelizumab as a high-efficacy RRMS DMT.^[5]
• Optic Neuritis Treatment Trial (ONTT) — established that high-dose IV steroids speed recovery from acute optic neuritis but do not improve final visual outcome; oral low-dose prednisolone alone increased recurrence (avoid); and it charted the high rate of MS conversion after optic neuritis with characteristic MRI lesions.^[1]

Regional practice contrasts:^[1]

• India — cost limits widespread monoclonal use; interferon-beta and glatiramer are the most accessible DMTs, with natalizumab, fingolimod and ocrelizumab available but expensive. The regional prevalence of AQP4-positive NMOSD is high (higher than in Caucasian populations), so AQP4 and MOG testing is mandatory before any DMT to avoid giving interferon to an NMOSD patient. Vitamin D deficiency is common and relevant to disease activity.
• UK — NICE (CG186 and Technology Appraisals) approve a defined DMT ladder with strict activity criteria; commissioning is via NHS England's specialised commissioning; MS specialist nurses coordinate care and are first contact for relapse.
• US — AAN practice guidelines guide DMT selection with a strong emphasis on shared decision-making and the early high-efficacy paradigm; insurance coverage shapes access.^[1]

Controversies:^[1]

• Escalation vs early high-efficacy induction — start with a safe moderate-efficacy drug and escalate at breakthrough, or induce with a high-efficacy monoclonal from the outset? Modern practice increasingly favours early high-efficacy in active disease, but the long-term safety of induction in young patients (decades of B-cell depletion) is unresolved.
• AHSCT — high efficacy in very active, treatment-refractory RRMS; reserved for specialist centres because of treatment-related mortality (under 1%) and late autoimmunity.
• The progressive MS therapy gap — current DMTs target inflammation; progressive axonal loss remains poorly addressed, with ocrelizumab and siponimod offering only modest benefit. Neuroprotective and remyelinating strategies are the active research frontier.^[1]

Exam pearls — MULTIPLE, the snapshot, the four courses

^{[1] [1]}

Exam application bank (NEET-PG / INICET)

One-line answer

Multiple sclerosis (MS) is a chronic, immune-mediated, inflammatory demyelinating disease of the central nervous system (CNS) defined by episodes of neurological dysfunction (disseminated in time and space) that, untreated, progress to irreversible disability. It is the commonest non-traumatic cause of neurological disability in young adults. Onset is typically between 20 and 40 years, female predominance about 3:1. About 85% present with relapsing-remitting MS (RRMS); 10 to 15% have primary progressive MS (PPMS) from onset. Diagnosis is clinical and anchored on the McDonald 2017 criteria — MRI showing periventricular, juxtacortical, infratentorial and spinal-cord plaques (Dawson fingers), with CSF oligoclonal bands (intrathecal IgG) substituting for dissemination in time. Acute relapse = IV methylprednisolone 1000 mg daily for 3 to 5 days; plasma exchange if steroid-refractory. Disease- ^[1]

Worked stems (answer without another resource)

Stem 1 — Classic presentation. Map symptoms to mechanism; name the first investigation and first treatment step with dose/route if drug therapy is standard. ^[1]

Stem 2 — Unstable / complicated. List red flags that force immediate resuscitation, theatre, ICU, antidote, or reperfusion — and what you do in the first 15 minutes. ^[1]

Stem 3 — Atypical group. Elderly, pregnancy, child, or immunocompromised: how presentation and thresholds change. ^[1]

Stem 4 — Differential trap. Name the three closest mimics and one discriminator for each. ^[1]

Stem 5 — Disposition. Who goes home with safety-netting, who is admitted, who needs HDU/ICU/theatre, and what follow-up is mandatory. ^[1]

Rapid viva checklist

1. Definition + classification
2. Pathophysiology chain
3. Bedside signs / criteria
4. Score with exact components (if any)
5. Emergency bundle
6. Definitive therapy with doses
7. Complications of disease and of treatment
8. Special populations
9. Guideline/trial name if classic
10. Three exam traps

Coverage self-check

If you cannot answer any stem above from this page alone, re-read the matching section — the page is intended to be self-sufficient for final-prof and NEET-PG/INICET questions on Multiple Sclerosis.

Ward-round test — four stems, thirty seconds each

The patient from the top of the topic — the 28-year-old with painful right visual loss and a relative afferent pupillary defect — plus three more the examiner loves. Answer each before you open the reveal.^[1]

Stem 1 — the corridor patient (answer)ShowHide

The 28-year-old: painful unilateral visual loss, RAPD, red desaturation, and a history of transient left-hand numbness six months ago. Diagnosis and first two steps? Model: Optic neuritis as a clinically isolated syndrome, disseminated in time (prior numbness) and space (optic nerve plus a cord or brain lesion to confirm on MRI). Arrange MRI brain and spine with gadolinium and CSF oligoclonal bands with a paired serum sample, and send AQP4-IgG and MOG-IgG before any DMT. Give IV methylprednisolone 1 g daily for 3 to 5 days to speed visual recovery (the ONTT regimen; it hastens recovery without changing final outcome). Apply McDonald 2017: CSF oligoclonal bands can substitute for dissemination in time, and symptomatic lesions now count.^[8][2]

Stem 2 — the wrong drug (answer)ShowHide

A 32-year-old woman is started on interferon-beta for 'MS' after one episode of severe bilateral optic neuritis and a cervical cord lesion spanning five segments. Three months later she is worse. What went wrong? Model: This was NMOSD, not MS — AQP4-IgG positive, severe bilateral optic neuritis with poor recovery, longitudinally extensive transverse myelitis (over 3 segments, central cord). The classic trap: interferon-beta is not recommended in NMOSD — it is at best ineffective and has been reported to trigger severe attacks, which is why AQP4 (and MOG) antibodies are checked before any DMT. Stop the interferon, confirm AQP4-IgG (and MOG-IgG), and switch to rituximab, mycophenolate, eculizumab or satralizumab (immunosuppression outperformed interferon in NMO cohorts). The one-line discriminator: AQP4-IgG plus longitudinally extensive transverse myelitis is NMOSD.^[24][25]

Stem 3 — deterioration on natalizumab (answer)ShowHide

A JCV-positive patient two years into natalizumab develops subacute cognitive decline and a left hemiparesis over three weeks. What is the diagnosis until proven otherwise, and what do you do today? Model: Progressive multifocal leukoencephalopathy until proven otherwise. Urgent MRI (large, confluent, asymmetric, typically non-enhancing subcortical T2 lesions) and CSF JCV DNA by PCR. Stop the natalizumab and arrange plasma exchange to accelerate clearance, watching for immune reconstitution inflammatory syndrome (IRIS). Re-state the risk stratification: JCV-positive plus over 24 months of treatment plus prior immunosuppression is the highest-risk stratum, up to about 1 in 100.^[7]

Stem 4 — the postpartum rebound (answer)ShowHide

A 30-year-old with RRMS stops her fingolimod in pregnancy and delivers a healthy baby. Six weeks later she has three relapses in a month. What happened, and what is the fix? Model: Two forces at once — the postpartum relapse rebound (in PRIMS the rate rose to about 1.2 relapses per woman-year in the first three months postpartum, above the pre-pregnancy rate) and fingolimod withdrawal (stopping it abruptly can trigger severe rebound disease, typically 2 to 4 months after cessation). The fix: treat each relapse with IV methylprednisolone 1 g daily for 3 to 5 days (safe postpartum and in breastfeeding), and bridge promptly to a high-efficacy DMT such as ocrelizumab rather than restarting fingolimod — never stop natalizumab or fingolimod abruptly without a bridge.^[22][27][31]

References32ShowHide

1. [1]Reich DS, Lucchinetti CF, Calabresi PA. Multiple Sclerosis N Engl J Med, 2018.PMID 29320652
2. [2]Thompson AJ, Banwell BL, Barkhof F, et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria Lancet Neurol, 2018.PMID 29275977
3. [3]Garg N, Smith TW. An update on immunopathogenesis, diagnosis, and treatment of multiple sclerosis Brain Behav, 2015.PMID 26445701
4. [4]Yamout BI, Alroughani R. Multiple Sclerosis Semin Neurol, 2018.PMID 29791948
5. [5]Hauser SL, Bar-Or A, Comi G, et al. Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis N Engl J Med, 2017.PMID 28002679
6. [6]Montalban X, Hauser SL, Kappos L, et al. Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis N Engl J Med, 2017.PMID 28002688
7. [7]Plavina T, Subramanyam M, Bloomgren G, et al. Anti-JC virus antibody levels in serum or plasma further define risk of natalizumab-associated progressive multifocal leukoencephalopathy Ann Neurol, 2014.PMID 25273271
8. [8]Beck RW, Cleary PA, Anderson MM Jr, et al. A randomized, controlled trial of corticosteroids in the treatment of acute optic neuritis N Engl J Med, 1992.PMID 1734247
9. [9]Burton JM, O'Connor PW, Hohol M, Beyene J. Oral versus intravenous steroids for treatment of relapses in multiple sclerosis Cochrane Database Syst Rev, 2012.PMID 23235634
10. [10]Berkovich RR. Acute Multiple Sclerosis Relapse Continuum (Minneap Minn), 2016.PMID 27261683
11. [11]Lipphardt M, Wallbach M, Koziolek MJ. Plasma Exchange or Immunoadsorption in Demyelinating Diseases: A Meta-Analysis J Clin Med, 2020.PMID 32466101
12. [12]Dorst J, Fangerau T, Taranu D, et al. Safety and efficacy of immunoadsorption versus plasma exchange in steroid-refractory relapse of multiple sclerosis and clinically isolated syndrome EClinicalMedicine, 2019.PMID 31832624
13. [13]IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial Neurology, 1993.PMID 8469318
14. [14]PRISMS Study Group. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis Lancet, 1998.PMID 9820297
15. [15]Comi G, Martinelli V, Rodegher M, et al. Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study) Lancet, 2009.PMID 19815268
16. [16]Kappos L, Radue EW, O'Connor P, et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis N Engl J Med, 2010.PMID 20089952
17. [17]Gold R, Kappos L, Arnold DL, et al. Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis N Engl J Med, 2012.PMID 22992073
18. [18]O'Connor P, Wolinsky JS, Confavreux C, et al. Randomized trial of oral teriflunomide for relapsing multiple sclerosis N Engl J Med, 2011.PMID 21991951
19. [19]Polman CH, O'Connor PW, Havrdova E, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis N Engl J Med, 2006.PMID 16510744
20. [20]Cohen JA, Coles AJ, Arnold DL, et al. Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial Lancet, 2012.PMID 23122652
21. [21]Sørensen PS, Bertolotto A, Edan G, et al. Risk stratification for progressive multifocal leukoencephalopathy in patients treated with natalizumab Mult Scler, 2012.PMID 22312009
22. [22]Confavreux C, Hutchinson M, Hours MM, Cortinovis-Tourniaire P, Moreau T. Rate of pregnancy-related relapse in multiple sclerosis. Pregnancy in Multiple Sclerosis Group N Engl J Med, 1998.PMID 9682040
23. [23]Krysko KM, Dobson R, Alroughani R, et al. Family planning considerations in people with multiple sclerosis Lancet Neurol, 2023.PMID 36931808
24. [24]Papeix C, Vidal JS, de Seze J, et al. Immunosuppressive therapy is more effective than interferon in neuromyelitis optica Mult Scler, 2007.PMID 17439893
25. [25]Kümpfel T, Giglhuber K, Aktas O, et al. Update on the diagnosis and treatment of neuromyelitis optica spectrum disorders (NMOSD) - revised recommendations of the Neuromyelitis Optica Study Group (NEMOS). Part II: Attack therapy and long-term management J Neurol, 2024.PMID 37676297
26. [26]Toosy A, Ciccarelli O, Thompson A. Symptomatic treatment and management of multiple sclerosis Handb Clin Neurol, 2014.PMID 24507534
27. [27]Barboza A, Gaitán MI, Alonso R, et al. Rebound activity after fingolimod cessation: A case-control study Mult Scler Relat Disord, 2022.PMID 35158443
28. [28]Fox RJ, Miller DH, Phillips JT, et al. Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis N Engl J Med, 2012.PMID 22992072
29. [29]Jakimovski D, Awan S, Eckert SP, et al. Multiple Sclerosis in Children: Differential Diagnosis, Prognosis, and Disease-Modifying Treatment CNS Drugs, 2022.PMID 34940954
30. [30]Simone IL, Tortorella C, Ghirelli A. Influence of Pregnancy in Multiple Sclerosis and Impact of Disease-Modifying Therapies Front Neurol, 2021.PMID 34276545
31. [31]Barry B, Erwin AA, Stevens J, Tornatore C. Fingolimod Rebound: A Review of the Clinical Experience and Management Considerations Neurol Ther, 2019.PMID 31677060
32. [32]Hartung HP, Aktas O, Boyko AN. Alemtuzumab: a new therapy for active relapsing-remitting multiple sclerosis Mult Scler, 2015.PMID 25344374